Tracking organ damage after GPA diagnosis predicts relapse risk

Tracking organ damage over the first year after a diagnosis of granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), predicts relapse risk more reliably than a single damage measurement early in the disease course, a study found. GPA patients whose cumulative damage score reached a…

A new study from Japan found that people with ANCA-associated vasculitis (AAV) have significantly higher levels of a protein known as AIM, fully apoptosis inhibitor of macrophage, in their urine than individuals without this vasculitis type — and these levels may be a useful way to monitor an individual’s…

Those of us with ANCA vasculitis can find ourselves in the hospital for a variety of reasons. If you’re on Medicare, there is a little-known caveat related to hospitalizations that are coded as outpatient for observation. I learned this the hard way and want to be sure you know…

Six-month remission rates with biosimilar versions of rituximab were similar to those seen with the original therapy among adults with the two most common types of ANCA-associated vasculitis (AAV), according to a real-world study in Canada. Data also showed no significant differences in serious adverse events or AAV-related…

The presence of clumps of inflammatory cells, or granulomas, in the liver is a rare manifestation of ANCA-associated vasculitis (AAV) that varies widely and can be difficult to diagnose, according to the findings of a new study from Tunisia. While liver problems are common in AAV, the researchers noted…

Every time a new ANCA vasculitis clinical trial is announced, I do the same little dance. I read the headline, feel a flicker of hope, and then scroll down to the eligibility criteria looking for one acronym: EGPA, which stands for “eosinophilic granulomatosis with polyangiitis.” Most of the time,…

Free-floating CD95L, a protein involved in inflammation and immune responses, is found at significantly higher levels in the blood of people with ANCA-associated vasculitis (AAV) and may be a potential treatment target, according to a study in France. Through a detailed series of experiments, researchers figured out that CD95L…

Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…

A few weeks ago, I was on a support group call for people with eosinophilic granulomatosis with polyangiitis when someone described how much it meant to be able to talk with other people in the same situation, and my friend responded, “It’s the power of many.” I have not been…

Kidney biopsy findings may help identify which adults with severe kidney involvement due to ANCA-associated vasculitis (AAV) are more likely to recover kidney function after treatment, a small study suggests. Data showed that patients with better kidney function at one year had a higher percentage of normal glomeruli —…